Search Results - "Moosmann, N"

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial by Modest, D.P., Jung, A., Moosmann, N., Laubender, R.P., Giessen, C., Schulz, C., Haas, M., Neumann, J., Boeck, S., Kirchner, T., Heinemann, V., Stintzing, S.

“…Our study investigated the impact of specific KRAS mutations and BRAF mutation on progression‐free survival (PFS) and overall survival (OS) in patients with…”
Get full text

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI by Alig, A.H.S., Modest, D.P., Stintzing, S., Heinrich, K., Geissler, M., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Held, S., Moosmann, N., Stahler, A., Tannapfel, A., Giessen-Jung, C., Jung, A., Weiss, L., Heinemann, V.

“…Primary tumor (PT) sidedness is an established prognostic marker in metastatic colorectal cancer (mCRC) and has a predictive impact on the efficacy of…”
Get full text

Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial by Kuon, J., Bozorgmehr, F., Schneider, M.A., Krisam, J., Lasitschka, F., Serke, M., Schuette, W., Moosmann, N., Gleiber, W., Faehling, M., Wermke, M., Schuett, P., Boesche, M., van Laak, V., Fischer von Weikersthal, L., Ulmer, M., Meyer zum Büschenfelde, C., Fischer, J.R., Thomas, M.

Get full text

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial by Stocker, G., Lorenzen, S., Ettrich, T., Herz, A.-L., Longo, F., Kiani, A., Venerito, M., Trojan, J., Mahlberg, R., Moosmann, N., Chibaudel, B., Kubicka, S., Greil, R., Daum, S., Geissler, M., Larcher-Senn, J., Keller, G., Lordick, F., Haag, G.M.

“…Platinum-fluoropyrimidine combinations are standard of care for treatment of metastatic esophagogastric adenocarcinoma. The optimal duration of first-line…”
Get full text

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial by Stintzing, S, Fischer von Weikersthal, L, Vehling-Kaiser, U, Stauch, M, Hass, H G, Dietzfelbinger, H, Oruzio, D, Klein, S, Zellmann, K, Decker, T, Schulze, M, Abenhardt, W, Puchtler, G, Kappauf, H, Mittermüller, J, Haberl, C, Giessen, C, Moosmann, N, Heinemann, V

“…Background: The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and…”
Get full text

Metastatic colorectal cancer--analysis of treatment modalities and survival now and then by Michl, M, Holtzem, B, Koch, J, Moosmann, N, Holch, J, Hiddemann, W, Heinemann, V

“…In metastatic colorectal cancer (mCRC) available systemic treatment options substantially increased in the last decades. Nowadays, overall survival in mCRC…”
Get more information

Erythroblastic synartesis in a patient initially diagnosed with myelodysplastic syndrome by Bacher, U, Lenz, G, Haferlach, T, Loeffler, H, Moosmann, N, Hiddemann, W, Ostermann, H

Get full text

1442P DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC) by Kuon, J.B., Blasi, M., Kokowski, K., Faehling, M., Schuette, W., Christoph, D.C.C., Kimmich, M., Engel-Riedel, W., Fischer, J.R., Lehmann, M., Ulmer, M., Schuett, P., Moosmann, N., Meyer zum Büschenfelde, C., Griesinger, F., Schneider, M., Behnisch, R., Stenzinger, A., Christopoulos, P., Thomas, M.

Get full text

1021P DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints by Kuon, J.B., Blasi, M., Kokowski, K., Faehling, M., Schuette, W., Christoph, D.C.C., Kimmich, M., Engel-Riedel, W., Fischer, J., Lehmann, M., Ulmer, M., Schuett, P., Moosmann, N., Meyer zum Bueschenfelde, C., Griesinger, F., Schneider, M., Behnisch, R., Stenzinger, A., Christopoulos, P., Thomas, M.

Get full text

1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO by Haag, G.M., Stocker, G., Lorenzen, S., Ettrich, T.J., Longo, F., Kiani, A., Venerito, M., Trojan, J., Mahlberg, R.J.C., Moosmann, N., Chibaudel, B., Kubicka, S., Greil, R., Daum, S., Geissler, M., Mann, J., Lordick, F.

Get full text

1871TiP PLATON – “Platform for Analyzing Targetable Tumor Mutations”: A pilot study by Vogel, A., Behringer, D.M., Bröckling, S., Chater, J., Derigs, H-G., Fietz, T., Götze, T.O., Hartmann, F., Lutz, M.P., Müller, L., Moosmann, N., Moulin, J-C., Potenberg, J., Saborowski, A., Späth-Schwalbe, E., Schuler, M.K., Pauligk, C., Westphalen, C.B., Zäpf, B., Al-Batran, S-E.

Get full text

Molecular-based treatment concepts in advanced pancreatic cancer by Boeck, S, Moosmann, N, Stemmler, H-J, Heinemann, V

Get more information

1508TiPDurvalumab in frail and elder patients with stage four NSCLC: The DURATION trial by Kuon, J, Bozorgmehr, F, Schneider, M A, Krisam, J, Lasitschka, F, Serke, M, Schuette, W, Moosmann, N, Gleiber, W, Faehling, M, Wermke, M, Schuett, P, Boesche, M, van Laak, V, Fischer von Weikersthal, L, Ulmer, M, Meyer zum Büschenfelde, C, Fischer, J R, Thomas, M

Get full text

Therapie schwerer akneiformer Cetuximab-Exantheme mit oralem Retinoid, topischem Antibiotikum und Steroidexternum by WOLLENBERG, A, MOOSMANN, N, KROTH, J, HEINEMANN, V, KLEIN, E

Get full text

Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid by Wollenberg, A, Moosmann, N, Kroth, J, Heinemann, V, Klein, E

“…The biological agent cetuximab specifically inhibits the epidermal growth factor receptor (EGFR) function. Cetuximab is licensed for treatment of metastatic…”
Get full text

A 78-year-old patient with hyperferritinemia, suspected hemochromatosis and mild anemia by Moosmann, N, Braess, J

Get full text

Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC) by Moosmann, N., Fischer von Weikersthal, L., Vehling-Kaiser, U., Stauch, M., Dietzfelbinger, H. F., Oruzio, D. V., Klein, S., Stintzing, S., Heinemann, V.

“…Abstract only…”
Get full text

Lymphadenopathy and constitutional symptoms. Progress of a low-grade follicular lymphoma? by Stemmler, H J, Hoelzl, M, Moosmann, N, Becker, C, Lennertz, A, Babaryka, G

“…Atypical presentation of Churg-Strauss syndrome includes lymph-node and parenchymatous organ involvement which mimics the clinical presentation of…”
Get full text

Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform exanthema caused by the EGFR-inhibitor cetuximab by Wollenberg, A., Katzer, K., Tietze, J., Moosmann, N., Kroth, J., Ruzicka, T., Heinemann, V.

“…Abstract only…”
Get full text

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial by Heinemann, V., Fischer von Weikersthal, L., Vehling-Kaiser, U., Stauch, M., Hass, H., Dietzfelbinger, H. F., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T., Schulze, M., Abenhardt, W., Puchtler, G., Kappauf, H. W., Mittermueller, J., Haberl, C., Giessen, C. A., Moosmann, N., Stintzing, S.

“…Abstract only…”
Get full text